| Description |
Taribavirin is an inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus[1].Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].
|
| Related Catalog |
|
| In Vitro |
Taribavirin (0-2 μM; 24 hours) significantly induces MCF-7 cell death, recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells[1]. Cell Viability Assay[1] Cell Line: MCF-7 cells Concentration: 0 μM, 0.1 μM, 1 μM, 2 μM Incubation Time: 24 hours Result: Decreased MCF-7 cell growth.
|
| References |
[1]. Abd-Rabou AA, et al. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27;35(4):76. [2]. Deming P, et al. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43.
|
